MATTERHORN Trial

Created using ChatSlide

A recent study published in the NEJM (Vol. 393, No. 3) explores the efficacy of adding Durvalumab to the FLOT regimen for stage II-IVA cancer patients, addressing the limitations of standard FLOT treatments. The Phase 3, double-blind trial involved 948 participants and showed significant improvements in event-free survival (67.4% vs. 58.5%) and overall survival rates (75.7% vs. 70.4%) with enhanced pathologic complete response rates. Despite an increase in immune-related adverse events (23.2%...